4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide has been researched along with Cephalgia Syndromes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crombie, A; Dripps, I; Moye, LS; Pradhan, AA; Sheets, Z; Tipton, AF; Violin, JD | 1 |
1 other study(ies) available for 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Cephalgia Syndromes
| Article | Year |
|---|---|
Delta opioid receptor agonists are effective for multiple types of headache disorders.
Topics: Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Headache Disorders; Hyperalgesia; Male; Mice; Morphine; Nitroglycerin; Piperazines; Receptors, Opioid, delta; Sumatriptan | 2019 |